Rivaroxaban versus placebo in patients with acute coronary syndromes (ATLAS ACS-TIMI 46): a randomised, double-blind, phase II trial.
about
RUBY-1: a randomized, double-blind, placebo-controlled trial of the safety and tolerability of the novel oral factor Xa inhibitor darexaban (YM150) following acute coronary syndromeDouble or triple antithrombotic combination therapy in patients who need anticoagulation and antiplatelet therapy in parallelStroke prevention in the elderly atrial fibrillation patient with comorbid conditions: focus on non-vitamin K antagonist oral anticoagulantsAnticoagulants for secondary prevention after acute myocardial infarction: lessons from the past decadeRivaroxaban in patients with a recent acute coronary syndrome event: integration of trial findings into clinical practiceClinical use of rivaroxaban: pharmacokinetic and pharmacodynamic rationale for dosing regimens in different indicationsRecent advances in treatment of acute coronary syndromesClinical pharmacokinetic and pharmacodynamic profile of rivaroxabanFactor XI and contact activation as targets for antithrombotic therapyComparative evaluation of direct thrombin and factor Xa inhibitors with antiplatelet agents under flow and static conditions: an in vitro flow chamber modelThe new oral anti-coagulants and the phase 3 clinical trials - a systematic review of the literatureAntithrombotic management in patients with percutaneous coronary intervention requiring oral anticoagulationDual pathway therapy in acute coronary syndrome.Selecting the optimal antithrombotic regimen for patients with acute coronary syndromes undergoing percutaneous coronary intervention.New and emerging anticoagulant therapy for atrial fibrillation and acute coronary syndrome.Pharmacokinetic evaluation of argatroban for the treatment of acute coronary syndrome.Pharmacotherapy with oral Xa inhibitors for venous thromboembolism.Switching between ticagrelor and clopidogrel in patients who underwent percutaneous coronary intervention: insight into contemporary practice in Chinese patientsUpdate in new medications for primary care.Preventive strategies against bleeding due to nonvitamin K antagonist oral anticoagulants.Balancing antiplatelet and anticoagulant therapies in patients with cardiovascular disease.New oral anticoagulants in addition to single or dual antiplatelet therapy after an acute coronary syndrome: a systematic review and meta-analysis.Novel oral anticoagulants: focus on stroke prevention and treatment of venous thrombo-embolism.Pharmacodynamic and pharmacokinetic basics of rivaroxaban.Evaluation of plaque stability of advanced atherosclerotic lesions in apo E-deficient mice after treatment with the oral factor Xa inhibitor rivaroxaban.Optimal oral antithrombotic regimes for patients with acute coronary syndrome: a network meta-analysisAcute myocardial infarction after switching from warfarin to dabigatran.Direct oral anticoagulants: key considerations for use to prevent stroke in patients with nonvalvular atrial fibrillation.Pharmacological and non pharmacological strategies in the management of coronary artery disease and chronic kidney diseasePopulation pharmacokinetics and pharmacodynamics of rivaroxaban in patients with acute coronary syndromes.Trend in young coronary artery disease in China from 2010 to 2014: a retrospective study of young patients ≤ 45.Potential role of rivaroxaban in patients with acute coronary syndromeRisk of Gastrointestinal Bleeding with Rivaroxaban: A Comparative Study with Warfarin.Relationship between ADP-induced platelet-fibrin clot strength and anti-platelet responsiveness in ticagrelor treated ACS patientsNew oral anticoagulant agents after ACS.An updated review of target-specific oral anticoagulants used in stroke prevention in atrial fibrillation, venous thromboembolic disease, and acute coronary syndromes.Mortality Risk Associated with AF in Myocardial Infarction Patients.Ischaemic cardiac outcomes in patients with atrial fibrillation treated with vitamin K antagonism or factor Xa inhibition: results from the ROCKET AF trial.Novel treatments for cardiovascular disease prevention.Balancing between bleeding and thromboembolism after percutaneous coronary intervention in patients with atrial fibrillation. Could triple anticoagulant therapy be a solution?
P2860
Q24623137-9ABC6F81-E756-4CB9-9F78-39477357BA9BQ26741058-560B8A39-FBF9-43E1-A709-80D596EEF119Q26781181-A738B1E5-85C4-4363-96FE-C98569F66914Q26824864-2D1A72AE-070E-422D-B62F-4D3437A3654FQ26825230-32B4D649-6911-446C-B562-184F19FE8EE2Q26828817-D027E427-AC99-4A0F-893D-363FAE954DF2Q26862897-4AE44FA8-AF57-4297-9273-B86BCCB0A169Q26864411-848CD280-9F57-47C7-A056-67D9AF72B442Q27024190-0F0E0F1E-0234-42D7-A7C3-857F07DE5570Q27330363-34FA6C50-2E65-441F-8D0A-56622AA8E8AEQ27497485-0490559D-F868-4CC2-9031-BF24756C5D58Q28072522-FA8309B5-48D4-4277-80A5-CF94AE0F931EQ30252011-878B7895-541B-4241-B00D-980144294C3AQ30438893-03F3DA08-23B2-4FA6-8002-10E99246B3E6Q33397359-7DA30322-8FA5-489C-9CD0-69FBBD8A45D0Q33403263-8DA25C9D-CBA0-4C88-9522-1A362DFDB571Q33419567-B91D1425-C828-480C-B44E-E5FB70ED9482Q33646807-BB5A6FD5-3541-4B41-9CEA-97E55FEDD802Q33730845-17B876F5-38C0-48A9-86A3-CA6E8E698072Q33854667-10CA9878-547A-4F83-9245-49D219A4FADFQ33936118-49639EBB-BB82-4501-ADE9-CD8D7060B512Q34331671-A23529F1-6933-43A5-924A-3CBF3D7EBAF0Q34627780-99A428CE-2137-4FED-BCFF-C37AA4F4DEFAQ34631714-D5A91F14-8257-463C-A315-8051CA615C42Q35099133-D07C5854-4FB3-4F64-BE58-838E0021A789Q35116512-970521B1-8C85-47AA-9307-5E24C2C338AFQ35211215-09436152-9A8D-4282-AE80-F8A9858C7726Q35746798-24D66C21-53DD-4D8C-9E11-AD9839247EF2Q36021782-DAC4CCE1-2640-480B-AA34-89178E716A20Q36087965-5816945F-B25B-477D-9F3C-AA65FD9251AEQ36243101-34CA116B-51E9-4D78-9F90-F465EB254292Q36433688-4346008A-9AE4-49A6-AFD7-10645A909599Q36531658-A41D6C17-8892-4F56-8B69-72C1C07FF5BBQ37039218-9D6A5ABB-297B-4724-914D-21776BE0A4F4Q37140964-C0F30608-1A35-42D5-84B5-B16B7EF6DF4CQ37328680-1EC46B78-9D3E-4B36-B741-DBD8E8060A63Q37496236-58253256-E7D4-423F-9DE1-4B3FD07F5555Q37497560-4A17FAEE-78FE-45BB-97A7-9C7361C6F762Q37548399-E08B0B37-B42E-4DDE-8C6A-38CBD588B052Q37561924-B03C04DE-ED87-4A4A-A28E-482339A982B9
P2860
Rivaroxaban versus placebo in patients with acute coronary syndromes (ATLAS ACS-TIMI 46): a randomised, double-blind, phase II trial.
description
2009 nî lūn-bûn
@nan
2009年の論文
@ja
2009年学术文章
@wuu
2009年学术文章
@zh-cn
2009年学术文章
@zh-hans
2009年学术文章
@zh-my
2009年学术文章
@zh-sg
2009年學術文章
@yue
2009年學術文章
@zh
2009年學術文章
@zh-hant
name
Rivaroxaban versus placebo in ...... double-blind, phase II trial.
@en
Rivaroxaban versus placebo in ...... double-blind, phase II trial.
@nl
type
label
Rivaroxaban versus placebo in ...... double-blind, phase II trial.
@en
Rivaroxaban versus placebo in ...... double-blind, phase II trial.
@nl
prefLabel
Rivaroxaban versus placebo in ...... double-blind, phase II trial.
@en
Rivaroxaban versus placebo in ...... double-blind, phase II trial.
@nl
P2093
P921
P1433
P1476
Rivaroxaban versus placebo in ...... double-blind, phase II trial.
@en
P2093
A Witkowski
ATLAS ACS-TIMI 46 study group
C M Gibson
E S Barnathan
F Misselwitz
L Oppenheimer
P356
10.1016/S0140-6736(09)60738-8
P407
P577
2009-06-17T00:00:00Z